SYNE3 Antibody

What is SYNE3 and what are its primary functions in cellular biology?

SYNE3 (Spectrin Repeat Containing Nuclear Envelope Family Member 3), also known as Nesprin-3, is a nuclear envelope protein that functions as a critical component of the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex. This protein enables actin filament binding activity and serves as a cytoskeleton-nuclear membrane anchor . At the molecular level, SYNE3:

• Facilitates the transmission of mechanical forces across the nuclear envelope

• Plays essential roles in nuclear movement and positioning

• Contributes to cytoskeleton organization and regulation of cell shape

• Anchors the nucleus to the cytoskeleton by binding PLEC (plectin), which associates with the intermediate filament system

• Influences aortic epithelial cell morphology

• Regulates flow-induced centrosome polarization and directional migration in aortic endothelial cells

The human version of SYNE3 has a canonical amino acid length of 975 residues and a protein mass of 112.2 kilodaltons, with three identified isoforms . It is notably expressed in the skin and testis and has been identified as a biomarker for Huntington's disease .

What is the relationship between Nesprin-3 and SYNE3 antibodies in scientific nomenclature?

Nesprin-3 and SYNE3 refer to the same protein target; they are synonyms in scientific nomenclature . Therefore, antibodies labeled as anti-Nesprin-3 or anti-SYNE3 target the same protein. The selection between these differently labeled antibodies should focus on characteristics such as:

• The specific epitope recognized (some target the N-terminal region or other specific domains)

• Host species in which the antibody was raised (rabbit, mouse, etc.)

• Clonality (monoclonal vs. polyclonal)

• Validated applications (WB, IHC, IF, etc.)

• Species reactivity profiles

Search term differences may yield varying results when searching databases, with "SYNE3" potentially returning more comprehensive results as the gene name, while "Nesprin-3" might be more commonly used in functional studies of the protein .

What are the optimal protocols for using SYNE3 antibodies in immunofluorescence studies?

For immunofluorescence studies using SYNE3/Nesprin-3 antibodies, the following protocol has demonstrated effectiveness:

Step-by-step immunofluorescence protocol:

• Collect cells and remove media using suction

• Wash with 1× PBS and remove

• Incubate cells in pre-warmed (37°C) paraformaldehyde for 12 minutes at room temperature on an orbital shaker

• Remove PFA and incubate in 0.5% Triton X-100 in 1× PBS for 5 minutes to permeabilize cells

• Wash cells twice with 1× PBS at room temperature, for 4 minutes per wash on an orbital shaker

• Block with 1% NCS (normal calf serum) in 1× PBS for 30 minutes at room temperature

• Prepare primary antibodies (50μl/coverslip) and moist staining chambers

• Wash cells twice with 1× PBS at room temperature and air dry briefly

• Incubate with SYNE3 primary antibody for 1 hour at room temperature in the dark in staining chambers

• Wash cells five times with 1× PBS (5 beaker washes)

For optimal results, researchers should determine appropriate antibody dilution through titration, with recommended starting dilutions between 1:500-1:2000 . When studying nuclear envelope localization, consider using confocal microscopy for better resolution of this narrow subcellular compartment.

How should SYNE3 antibody dilutions be optimized for Western blot analysis?

Optimizing SYNE3 antibody dilutions for Western blot requires a systematic approach:

Recommended protocol for Western blot optimization:

• Initial concentration range: Begin with 0.04-0.4 μg/mL as recommended for anti-SYNE3 antibodies

• Perform a dilution series (e.g., 1:500, 1:1000, 1:2000, 1:5000) using known positive samples

• Evaluate results based on:

  • Signal strength at the expected molecular weight (112.2 kDa for canonical SYNE3 )

  • Specificity (presence of single band vs. multiple bands)

  • Background noise levels

• Select the dilution providing the best signal-to-noise ratio

Additional optimization parameters:

For SYNE3 detection, particular attention should be paid to extraction protocols, as nuclear envelope proteins may require specialized lysis buffers to ensure efficient solubilization and transfer .

What fixation and staining methods are recommended for SYNE3 immunohistochemistry?

For immunohistochemical analysis of SYNE3 expression in tissue samples, the following methods have been validated:

Tissue preparation:

• Fix tissue specimens in neutral buffered formalin

• Process and embed in paraffin

• Section paraffin blocks to approximately 4 μm thickness

Staining protocol:

• Deparaffinize and rehydrate sections through graded alcohols

• Perform antigen retrieval (heat-induced epitope retrieval in citrate buffer pH 6.0 is often effective)

• Block endogenous peroxidase activity with hydrogen peroxide solution

• Apply protein blocking solution

• Incubate with anti-SYNE3 antibody at dilutions of 1:500-1:1000

• Detect using the Streptavidin-Peroxidase (SP) method

• Counterstain, dehydrate, and mount

For validation and comparative studies, kidney tissue serves as an effective positive control for SYNE3 antibodies . When analyzing results, note that SYNE3 typically shows nuclear envelope localization, and quantification can be performed using digital image analysis to calculate the percentage of positive cells as demonstrated in studies of SYNE3 expression in non-small cell lung cancer tissues .

How can SYNE3 antibodies be employed to study nuclear-cytoskeletal connections?

SYNE3's role as a component of the LINC complex makes it valuable for investigating nuclear-cytoskeletal connections through several sophisticated approaches:

Co-localization studies:
Combine immunofluorescence with SYNE3 antibodies and markers for cytoskeletal elements (particularly intermediate filaments via plectin, which SYNE3 binds) . Use:

• Super-resolution microscopy techniques (STORM, STED, SIM) to resolve the nanoscale organization at the nuclear envelope

• Z-stack imaging to capture the three-dimensional relationship between SYNE3 and cytoskeletal components

• Quantitative co-localization analysis (Pearson's correlation, Manders' coefficients)

Proximity ligation assays (PLA):
This technique allows visualization of protein-protein interactions when proteins are within 40nm of each other:

• Apply primary antibodies against SYNE3 and potential interacting partners

• Use secondary antibodies conjugated with complementary oligonucleotides

• When proteins are in close proximity, oligonucleotides can be ligated and amplified

• Detect fluorescent signal indicating interaction

Immunoprecipitation-based approaches:
Use SYNE3 antibodies to isolate protein complexes and identify cytoskeletal binding partners:

• Cross-link protein complexes in intact cells

• Lyse cells and immunoprecipitate with SYNE3 antibodies

• Analyze by mass spectrometry or Western blotting for cytoskeletal proteins

• Validate interactions with reverse co-immunoprecipitation

Mechanotransduction studies:
Investigate SYNE3's role in force transmission using:

• Applied mechanical stimuli (stretch, compression, shear flow)

• Live cell imaging of SYNE3 dynamics during force application

• Assessment of nuclear deformation and cytoskeletal reorganization

• Correlation with mechanosensitive signaling pathways

What is known about SYNE3 expression in cancer and how can antibodies help characterize this?

Research into SYNE3's role in cancer is emerging, with notable findings in non-small cell lung cancer (NSCLC):

NSCLC expression profile:

• Studies have examined SYNE3 expression in NSCLC tissues compared to adjacent normal tissues

• Immunohistochemical analysis using SYNE3 antibodies has been employed to assess expression patterns

• CD34 (an endothelial marker) has been co-evaluated to investigate the relationship between SYNE3 and tumor angiogenesis

• CD34-marked microvessel density (MVD) in lung cancer tissues was significantly higher than in adjacent normal tissues

• MVD significantly correlated with clinical stage in NSCLC

Methodological approach for cancer studies:

• Collect paired tumor and adjacent normal tissue samples

• Perform immunohistochemistry using validated SYNE3 antibodies

• Assess expression patterns (intensity, subcellular localization, heterogeneity)

• Correlate with clinicopathological parameters (stage, grade, survival)

• Consider co-staining with markers of relevant processes (e.g., angiogenesis, EMT)

• Validate findings with orthogonal methods (qRT-PCR, Western blot)

This approach can be extended to other cancer types to build a comprehensive understanding of SYNE3's potential role in cancer biology and its value as a biomarker or therapeutic target .

How can computational approaches improve antibody specificity for SYNE3 detection?

Recent advances in computational biology offer promising approaches to enhance antibody specificity for SYNE3 detection:

Biophysics-informed modeling:
Novel computational approaches can:

• Identify different binding modes associated with particular ligands

• Disentangle binding contributions from closely related epitopes

• Enable prediction and generation of specific variants beyond those observed experimentally

Model-guided antibody design process:

• Perform initial phage display experiments with antibody libraries against SYNE3

• Collect high-throughput sequencing data from selected antibodies

• Develop biophysical models that associate energy functions with different binding modes

• Use these models to design novel antibody sequences with:

  • Specific high affinity for SYNE3 (minimizing cross-reactivity)

  • Cross-specificity for multiple target ligands (if desired)

  • Reduced experimental artifacts and selection biases

Active learning for improved antibody-antigen prediction:
Recent research demonstrates that active learning strategies can improve experimental efficiency:

• Start with a small labeled subset of antibody-antigen binding data

• Iteratively expand the labeled dataset using strategic selection criteria

• Reduce the number of required antigen variants by up to 35%

• Accelerate the learning process compared to random sampling approaches

These computational approaches provide powerful tools for designing antibodies with desired specificity profiles, potentially leading to more precise SYNE3 detection reagents.

Troubleshooting and Validation

When SYNE3 antibodies exhibit weak or nonspecific signals, systematic troubleshooting is required:

Common issues and solutions:

• Weak or absent signal

  • Protein extraction challenges: SYNE3 is a nuclear envelope protein that may require specialized extraction methods

    • Solution: Use nuclear extraction buffers containing appropriate detergents (NP-40, Triton X-100)

  • Antibody concentration too low

    • Solution: Titrate antibody, starting with manufacturer's recommendation (0.04-0.4 μg/mL for Western blot )

  • Epitope masking during fixation

    • Solution: Optimize fixation conditions or try different antigen retrieval methods

  • Sample preparation issues

    • Solution: For Western blot, ensure complete transfer of large proteins like SYNE3 by using extended transfer times or lower methanol concentration

• High background or nonspecific signals

  • Insufficient blocking

    • Solution: Extend blocking time (60 minutes minimum) and optimize blocking reagent (BSA vs. milk)

  • Antibody concentration too high

    • Solution: Titrate to find optimal concentration that balances signal and background

  • Cross-reactivity with related proteins

    • Solution: Select antibodies targeting unique regions of SYNE3

    • Consider pre-absorbing antibody against related proteins

  • Detection system sensitivity issues

    • Solution: Use more sensitive detection methods (amplified chemiluminescence, fluorescent detection)

Optimized immunohistochemistry protocol to reduce background:

• Use freshly prepared buffers and reagents

• Include Triton X-100 (0.1-0.3%) in antibody diluent to reduce hydrophobic interactions

• Increase number and duration of washes between steps

• Block endogenous peroxidase with 3% hydrogen peroxide before antibody application

• For fluorescent detection, include an autofluorescence quenching step

Methodical optimization of these parameters typically resolves most signal and specificity issues with SYNE3 antibodies.

How can researchers distinguish between genuine SYNE3 isoforms and non-specific antibody binding?

Distinguishing genuine SYNE3 isoforms from non-specific binding requires careful experimental design:

Isoform characterization strategy:

• Molecular weight analysis

  • The canonical SYNE3 has a molecular weight of 112.2 kDa

  • The three known isoforms will have predictable molecular weights

  • Run high-resolution SDS-PAGE with molecular weight markers

  • Compare observed bands with theoretical molecular weights of known isoforms

• Isoform-specific detection

  • Use antibodies targeting regions common to all isoforms for pan-SYNE3 detection

  • Where possible, obtain isoform-specific antibodies targeting unique regions

  • Compare staining/blotting patterns between pan-SYNE3 and isoform-specific antibodies

• Expression system controls

  • Express individual SYNE3 isoforms in cell systems

  • Use these as positive controls to identify isoform-specific bands/patterns

  • Create mixed samples with known ratios of isoforms to validate detection sensitivity

• Complementary nucleic acid analysis

  • Perform RT-PCR with isoform-specific primers to correlate mRNA expression with protein detection

  • Use RNAseq data to identify which isoforms are expressed in your experimental system

• Mass spectrometry validation

  • Immunoprecipitate SYNE3 using validated antibodies

  • Analyze by mass spectrometry to identify peptides specific to different isoforms

  • Quantify relative abundance of isoform-specific peptides

Decision tree for distinguishing specific from non-specific signals:

• Does the band/signal appear at the predicted molecular weight for a known SYNE3 isoform?

• Is the signal eliminated by SYNE3 knockdown/knockout?

• Is the pattern consistent across multiple antibodies targeting different SYNE3 epitopes?

• Does the signal correlate with mRNA expression of specific isoforms?

• Is the subcellular localization consistent with known SYNE3 distribution (nuclear envelope)?

If the answer is "yes" to most of these questions, the signal likely represents genuine SYNE3 isoforms rather than non-specific binding.

How can SYNE3 antibodies contribute to studying mechanotransduction in cellular systems?

SYNE3's position in the LINC complex makes it ideally suited for mechanotransduction research using specialized antibody applications:

Experimental approaches for mechanotransduction studies:

• Force-induced conformational changes

  • Apply mechanical forces (stretch, compression, shear stress) to cells

  • Use conformation-specific SYNE3 antibodies to detect structural changes

  • Compare staining patterns before and after force application

  • Correlate with activation of mechanosensitive signaling pathways

• Dynamic protein interactions under mechanical stimulation

  • Perform co-immunoprecipitation with SYNE3 antibodies under different mechanical conditions

  • Identify force-dependent interaction partners

  • Use proximity ligation assays to visualize force-induced protein associations in situ

• Live cell mechanobiology

  • Develop non-disruptive antibody fragments (Fab, nanobodies) against SYNE3

  • Label with fluorescent tags for live imaging during force application

  • Track SYNE3 dynamics during mechanical challenge

  • Correlate with nuclear deformation and cellular responses

• Flow-induced polarity and migration studies

  • Apply shear flow to endothelial cells (where SYNE3 is required for flow-induced centrosome polarization)

  • Use SYNE3 antibodies to track redistribution during polarization

  • Co-stain for centrosome and cytoskeletal markers

  • Quantify temporal relationship between SYNE3 reorganization and directional migration

These approaches leverage SYNE3 antibodies to illuminate the molecular mechanisms of mechanotransduction at the nuclear envelope.

What is the significance of SYNE3 in disease pathology beyond cancer, and how can antibodies aid this research?

While SYNE3 research has focused on cancer applications, evidence suggests broader disease relevance:

SYNE3 in Huntington's disease:

• SYNE3 has been identified as a biomarker of Huntington's disease

• Antibody-based studies can help elucidate mechanism by:

  • Comparing SYNE3 expression/localization in patient vs. control samples

  • Investigating SYNE3 interactions with huntingtin protein

  • Examining nuclear envelope integrity in affected tissues

Potential role in other neurodegenerative disorders:

• Nuclear envelope dysfunction is implicated in several neurodegenerative conditions

• SYNE3 antibodies can be used to:

  • Screen tissue banks of various neurodegenerative disorders for SYNE3 abnormalities

  • Investigate nuclear envelope integrity in disease models

  • Explore correlations between SYNE3 expression/localization and disease progression

SYNE3 in cardiovascular disease:

• Given SYNE3's role in aortic epithelial cell morphology and flow-induced polarization

• Research opportunities include:

  • Examining SYNE3 in atherosclerosis-prone vs. resistant vascular regions

  • Studying SYNE3 changes during vascular remodeling

  • Investigating SYNE3 in mechanotransduction defects in vascular pathologies

Methodological approach for disease studies:

• Perform comparative analysis of SYNE3 in affected vs. healthy tissues using validated antibodies

• Correlate with disease severity markers and patient outcomes

• Develop disease-relevant cell and animal models

• Test manipulations of SYNE3 expression/function on disease phenotypes

• Investigate potential as diagnostic biomarker or therapeutic target

How might machine learning enhance SYNE3 antibody design and specificity profiling?

Cutting-edge computational approaches are transforming antibody design for challenging targets like SYNE3:

Advanced computational design strategies:

• Biophysics-informed modeling for antibody specificity

  • Models can disentangle different binding modes associated with specific ligands

  • This enables prediction and generation of antibodies beyond those observed experimentally

  • Can design antibodies with customized specificity profiles for SYNE3:

    • High specificity for a particular target epitope

    • Cross-specificity for multiple target ligands if desired

    • Reduced experimental artifacts and biases

• Active learning for antibody-antigen binding prediction

  • Reduces experimental costs by strategically selecting which experiments to perform

  • Recent research demonstrated:

    • Up to 35% reduction in required antigen variants

    • Significant acceleration of the learning process compared to random sampling

    • Improved out-of-distribution prediction performance

• Library-on-library approach optimization

  • Machine learning models can analyze many-to-many relationships between antibodies and antigens

  • Predict interactions when test antibodies and antigens aren't in training data

  • Fourteen novel active learning strategies have been evaluated specifically for antibody-antigen binding prediction

• Structural fragment-based design

  • Uses computational methods to identify structural fragments suitable for antibody binding sites

  • Can specifically design binding sites targeting unique SYNE3 epitopes

  • Enables rational rather than purely experimental antibody engineering

The integration of these computational approaches with experimental validation creates a powerful pipeline for developing next-generation SYNE3-specific antibodies with enhanced performance characteristics.